BR112014031556A2 - derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer - Google Patents

derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer

Info

Publication number
BR112014031556A2
BR112014031556A2 BR112014031556A BR112014031556A BR112014031556A2 BR 112014031556 A2 BR112014031556 A2 BR 112014031556A2 BR 112014031556 A BR112014031556 A BR 112014031556A BR 112014031556 A BR112014031556 A BR 112014031556A BR 112014031556 A2 BR112014031556 A2 BR 112014031556A2
Authority
BR
Brazil
Prior art keywords
cancer therapy
related compounds
medical use
bendamustine
bendamustine derivatives
Prior art date
Application number
BR112014031556A
Other languages
English (en)
Other versions
BR112014031556B1 (pt
Inventor
Armin Buschauer
Christian Schickaneder
Günther Bernhardt
Harald Hofmeier
Helmut Schickaneder
Mathias Lubbe
Michael Limmert
Stefan Huber
Original Assignee
Helmut Schickaneder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmut Schickaneder filed Critical Helmut Schickaneder
Publication of BR112014031556A2 publication Critical patent/BR112014031556A2/pt
Publication of BR112014031556B1 publication Critical patent/BR112014031556B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo “derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer” a presente invenção refere-se a derivados de bendamustina e compostos relacionados de fórmula geral (vii), (viii) e (ix), e usos médicos dos mesmos, em particular, na terapia do câncer.
BR112014031556-6A 2012-06-19 2013-06-14 derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer BR112014031556B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661374P 2012-06-19 2012-06-19
US201261670158P 2012-07-11 2012-07-11
PCT/EP2013/062347 WO2013189847A1 (en) 2012-06-19 2013-06-14 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy

Publications (2)

Publication Number Publication Date
BR112014031556A2 true BR112014031556A2 (pt) 2015-12-22
BR112014031556B1 BR112014031556B1 (pt) 2019-10-29

Family

ID=48628661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031556-6A BR112014031556B1 (pt) 2012-06-19 2013-06-14 derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer

Country Status (13)

Country Link
US (2) US10526290B2 (pt)
EP (1) EP2861564B1 (pt)
JP (1) JP6153606B2 (pt)
KR (1) KR101955065B1 (pt)
CN (1) CN104395296A (pt)
BR (1) BR112014031556B1 (pt)
CA (1) CA2875455C (pt)
ES (1) ES2694757T3 (pt)
HK (1) HK1209725A1 (pt)
MX (1) MX365192B (pt)
RU (1) RU2695383C2 (pt)
UA (1) UA117809C2 (pt)
WO (1) WO2013189847A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452988B2 (en) 2012-11-12 2016-09-27 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2886536A1 (en) * 2013-12-19 2015-06-24 Helmut Schickaneder Bendamustine derivatives as anti-proliferative agents
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
BR112020009285A2 (pt) 2017-11-13 2020-10-27 Ecolab Usa Inc. composição, processo para produzir um composto ou sal, uso de uma composição, e, método para inibir corrosão

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD34727A1 (de) * 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
AU6859394A (en) * 1993-05-25 1994-12-20 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EP1939194A4 (en) * 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
CN102177140B (zh) * 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
PL2656843T3 (pl) * 2012-04-26 2015-08-31 Synbias Pharma Ag Estry bendamustyny i związki pokrewne i ich medyczne zastosowanie

Also Published As

Publication number Publication date
CN104395296A (zh) 2015-03-04
US20170313663A1 (en) 2017-11-02
KR101955065B1 (ko) 2019-03-06
CA2875455C (en) 2020-03-10
CA2875455A1 (en) 2013-12-27
US10526290B2 (en) 2020-01-07
WO2013189847A1 (en) 2013-12-27
ES2694757T3 (es) 2018-12-27
MX365192B (es) 2019-05-23
HK1209725A1 (en) 2016-04-08
US10294208B2 (en) 2019-05-21
EP2861564B1 (en) 2018-08-08
BR112014031556B1 (pt) 2019-10-29
UA117809C2 (uk) 2018-10-10
US20150152066A1 (en) 2015-06-04
KR20150020581A (ko) 2015-02-26
EP2861564A1 (en) 2015-04-22
MX2014014895A (es) 2015-06-17
JP2015520200A (ja) 2015-07-16
JP6153606B2 (ja) 2017-06-28
RU2695383C2 (ru) 2019-07-23
RU2014146896A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
BR112015011830A2 (pt) compostos e seus métodos de utilização
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
EA201690495A1 (ru) Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112015022551A2 (pt) inibidores de amido pirrol
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
CO7350640A2 (es) Compuestos diméricos
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112015023161A2 (pt) derivados de piridin-4-ila
GB201209587D0 (en) Therapeutic compounds
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BR112015028876A2 (pt) derivados de perhidroquinoxalina
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SYNBIAS PHARMA AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2013, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2013, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2674 DE 05-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.